Alan Tan· @alantanmd · X·· 22 小时前评分70
正文 · 原文
@tompowles1 presented VOLGA at #ESMO26: perioperative durvalumab + neoadjuvant EV vs control in cisplatin-ineligible MIBC
▪️ EFS HR 0.51, p<0.0001
▪️ OS HR 0.58, p=0.0027
▪️ pCR 45% vs 10%
@apolo_andrea @PGrivasMDPhD @shilpaonc @montypal Niklas Klümper #BladderCancer
130 浏览 · 2 赞 · 2 转发 · 0 回复
会议摘要
LBA2按 Presidential Symposium I 对上
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.org来源：Alan Tan · x.com